BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...mergers like Nuvation, Cerevel Therapeutics LLC and Gemini Therapeutics Inc....
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...will improve the products’ profitability.Gemini lands on NASDAQ via merger with Foresite’s SPACRetinal disease company Gemini Therapeutics Inc....
...GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) Endo International plc BioSpecifics Technologies Corp. Foresite Capital Management Gemini Therapeutics Inc. Catalyst...
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

...as part of the French antibody company’s expansion into the U.S. Knopf was CBO of Gemini Therapeutics Inc....
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...Inc. The Harvard University spinout is developing cell-penetrating miniproteins to treat cancer. Ophthalmic diseases company Gemini Therapeutics Inc....
...of commercial development at Pfizer Inc. (NYSE:PFE) in 2009-12. Robin Sawka, BioCentury Staff TG Therapeutics Inc. FOG Pharmaceuticals Inc. Gemini Therapeutics Inc. Dicerna...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc....
...Therapeutics Inc. Rallybio LLC Milestone Pharmaceuticals Inc. Gritstone Oncology Inc. I-Mab Biopharma Pfizer Inc. MaaT Pharma S.A. Celcuity Inc. ALK-Abello A/S Menarini Group Orchard Therapeutics plc Gemini Therapeutics Inc....
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...VP of Finance Allison Dorval will serve as principal financial officer and principal accounting officer. Gemini Therapeutics Inc....
BioCentury | Oct 20, 2017
Finance

Stars align for rare AMD

...Investors have backed Gemini Therapeutics Inc. with a $42.5 million series A round so the company can use...
...has raised an undisclosed seed financing from Syncona Ltd. (LSE:SYNC) and Cambridge Enterprise. Stephen Hansen, Associate Editor Gemini Therapeutics Inc....
BioCentury | Oct 20, 2017
Financial News

Gemini raises $42.5M series A

...On Oct. 17, Gemini Therapeutics Inc. (Cambridge, Mass.) raised $42.5 million in a series A round co-led by...
...investors participated in the company's undisclosed seed financing last year. Gemini Therapeutics Inc. , Cambridge, Mass. Mary Romeo Atlas Venture Gemini Therapeutics Inc....
BioCentury | Oct 17, 2017
Financial News

Gemini raises $42.5M in series A

Gemini Therapeutics Inc. (Cambridge, Mass.) raised $42.5 million in a series A round co-led by Atlas Venture, Lightstone Ventures and OrbiMed Advisors. The company is developing therapies for complement-mediated diseases, with an initial focus on...
Items per page:
1 - 9 of 9
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...mergers like Nuvation, Cerevel Therapeutics LLC and Gemini Therapeutics Inc....
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...will improve the products’ profitability.Gemini lands on NASDAQ via merger with Foresite’s SPACRetinal disease company Gemini Therapeutics Inc....
...GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) Endo International plc BioSpecifics Technologies Corp. Foresite Capital Management Gemini Therapeutics Inc. Catalyst...
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

...as part of the French antibody company’s expansion into the U.S. Knopf was CBO of Gemini Therapeutics Inc....
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...Inc. The Harvard University spinout is developing cell-penetrating miniproteins to treat cancer. Ophthalmic diseases company Gemini Therapeutics Inc....
...of commercial development at Pfizer Inc. (NYSE:PFE) in 2009-12. Robin Sawka, BioCentury Staff TG Therapeutics Inc. FOG Pharmaceuticals Inc. Gemini Therapeutics Inc. Dicerna...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc....
...Therapeutics Inc. Rallybio LLC Milestone Pharmaceuticals Inc. Gritstone Oncology Inc. I-Mab Biopharma Pfizer Inc. MaaT Pharma S.A. Celcuity Inc. ALK-Abello A/S Menarini Group Orchard Therapeutics plc Gemini Therapeutics Inc....
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...VP of Finance Allison Dorval will serve as principal financial officer and principal accounting officer. Gemini Therapeutics Inc....
BioCentury | Oct 20, 2017
Finance

Stars align for rare AMD

...Investors have backed Gemini Therapeutics Inc. with a $42.5 million series A round so the company can use...
...has raised an undisclosed seed financing from Syncona Ltd. (LSE:SYNC) and Cambridge Enterprise. Stephen Hansen, Associate Editor Gemini Therapeutics Inc....
BioCentury | Oct 20, 2017
Financial News

Gemini raises $42.5M series A

...On Oct. 17, Gemini Therapeutics Inc. (Cambridge, Mass.) raised $42.5 million in a series A round co-led by...
...investors participated in the company's undisclosed seed financing last year. Gemini Therapeutics Inc. , Cambridge, Mass. Mary Romeo Atlas Venture Gemini Therapeutics Inc....
BioCentury | Oct 17, 2017
Financial News

Gemini raises $42.5M in series A

Gemini Therapeutics Inc. (Cambridge, Mass.) raised $42.5 million in a series A round co-led by Atlas Venture, Lightstone Ventures and OrbiMed Advisors. The company is developing therapies for complement-mediated diseases, with an initial focus on...
Items per page:
1 - 9 of 9